Please ensure Javascript is enabled for purposes of website accessibility
Inicio > Productos > Anticuerpos > Biosimilares

Anti-Human TRANCE/TNFSF11/RANK L Reference Antibody (Denosumab, RUO) (HT439016)

Anti-Human TRANCE/TNFSF11/RANK L Reference Antibody (Denosumab, RUO)
Anti-Human TRANCE/TNFSF11/RANK L Reference Antibody (Denosumab, RUO)
Precio(USD):
Especificación:
  • 100ug
  • 1mg
  • 5mg
  • 10mg
  • 25mg
  • 50mg
  • 100mg
Número:
Contáctenos
  • Vista general

  • Imágenes

  • Referencias

  • Datasheet

  • SDS

Vista general
Número de catálogoHT439016
Descripción
Denosumab (HT439016) is a research-grade recombinant antibody targeting CD254. Produced in mammalian cells with native-like glycosylation.
Highlights
  • ●Research Grade — For PK/PD studies, assay development, and ADA research.
  • ●Native Glycosylation — Mammalian expression ensures native-like patterns.
Reactividad de especiesHuman
AplicacionesELISA, Bioactivity: FACS, Functional assay, Research in vivo
Especie huéspedHuman
ClonalidadMonoclonal
IsotipoIgG2-kappa
Sistema de expresión Mammalian cells
Objetivo ODF, TNF-related activation-induced cytokine, Osteoclast differentiation factor, TNFSF11, TRANCE, Osteoprotegerin ligand, RANKL, Tumor necrosis factor ligand superfamily member 11, Receptor activator of nuclear factor kappa-B ligand, CD254, OPGL
Nivel de endotoxinas < 10 EU/mg
Pureza >95% purity as determined by SDS-PAGE.
Purificación Protein A/G purified from cell culture supernatant.
Número de acceso O14788
Forma Liquid
Buffer de almacenamiento 0.01M PBS pH 7.4

Consulte la información específica del buffer en la copia impresa del datasheet o en el COA específico del lote.

Estabilidad y almacenamiento Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Nombres alternativosAMG162, 615258-40-7
Fondo

Tumor necrosis factor ligand superfamily member 11 (CD254/RANKL) is a ~35 kDa protein. Cytokine that binds to TNFRSF11B/OPG and to TNFRSF11A/RANK. Osteoclast differentiation and activation factor. Augments the ability of dendritic cells to stimulate naive T-cell proliferation. May be an important regulator of interactions between T-cells and dendritic cells and may play a role in the regulation of the T-cell-dependent immune response. May also play an important role in enhanced bone-resorption in humoral hypercalcemia of malignancy. CD254 is the therapeutic target of denosumab (Prolia).

1. Luan, X. et al. (2012) Journal of immunology (Baltimore, Md. : 1950) 189, 245-52. PMID: 22664871
Nota For research use only. Not suitable for clinical or therapeutic use.
Isotype Control Human IgG2 Recombinant Isotype Control Antibody (HyHEL-10) (HV988107)
Imágenes
  • Anti-Human TRANCE/TNFSF11/RANK L Reference Antibody (Denosumab, RUO)

    SDS-PAGE

    SDS-PAGE for Research Grade Denosumab.

Referencias
Formula
Mass (g) = Concentration (mol/L) × Volume (L) × MW (g/mol)
Enter any 2 of Mass, Concentration, Volume + Molecular Weight to solve for the unknown.
Mass
=
Concentration
×
Volume
Molecular Weight *
g/mol
Formula
C₁ × V₁ = C₂ × V₂
Enter any 3 of the 4 values to solve for the unknown.
Stock Solution
C₁ (Stock Conc.)
×
V₁ (Stock Vol.)
=
Working Solution
C₂ (Working Conc.)
×
V₂ (Working Vol.)
Recomendación

Contáctenos para cotizaciones personalizadas, solicitudes en masa y cualquier otro problema.

Correo: [email protected]

Lista de distribuidores